
September 14, 2026

The Honorable John Thune
Majority Leader
US Senate
S-230 Capitol Building
Washington, DC 20510

The Honorable Charles Schumer
Minority Leader
US Senate
S-221 Capitol Building
Washington, DC 20510

The Honorable Mike Johnson
Speaker of the House
US House of Representatives
H-232 Capitol Building
Washington, DC 20515

The Honorable Hakeem Jeffries
Minority Leader
US House of Representatives
H-204 Capitol Building
Washington, DC 20515

Dear Leader Thune, Leader Schumer, Speaker Johnson, and Leader Jeffries,

On behalf of the undersigned organizations, we write to urge you to include a comprehensive reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) in a legislative package before the end of the 119th Congressional Session.

This year marks the 20th anniversary of the passage of the original PAHPA, which created the statutory backbone for American health preparedness and response capabilities. Negotiations are underway on a new reauthorization bill that would make critical improvements to our nation's health security programs, originally authorized in PAHPA. These programs in the Administration for Strategic Preparedness and Response (ASPR), which include the Strategic National Stockpile (SNS) and the Biomedical Advanced Research and Development Authority (BARDA), will be called upon to prevent, prepare for, and respond to any national health security threats.

These threats—whether they emerge from advances in biotechnology and artificial intelligence, naturally occurring outbreaks, major storms, deliberate attacks, or accidents—require an agile, authorized, responsive government infrastructure.

The PAHPA framework expired on September 30, 2023, requiring repeated stopgap, temporary extensions to keep these critical national health security programs authorized. Relying on last-minute, short-term extensions is not sustainable and jeopardizes American health security. We urge you to pass a comprehensive PAHPA reauthorization package, one that includes key new provisions that strengthen US preparedness and response capabilities, before the end of the year.

The last three PAHPA reauthorization packages shared major recurring themes: they all adjusted to the changing threat landscape, focused on challenges identified since the prior bill, and strengthened our nation's health security with each reauthorization. A new reauthorization bill would continue to do that by strengthening existing programs and continuing to adapt and improve America's health security infrastructure for new and future challenges.

Failing to reauthorize PAHPA now would have serious effects on our country's economic wellbeing, national security, and health given the rapidly changing threat

landscape. For example, Congress would leave critical preparedness programs—like the Strategic National Stockpile, medical countermeasure and PPE development and procurement, medical supply chain resilience, and hospital preparedness programs—without clear direction and oversight.

We are hopeful that PAHPA will remain a strong bipartisan legislative framework, as it has always been. We stand ready to assist you however we can to help get this important law reauthorized this year.

Thank you for your attention to this critical matter; please contact Joel Straus at joel.straus@jhu.edu with any questions.

Sincerely (in alphabetical order),

Adjuvant Capital

Aequor Inc.

Alliance for Biosecurity

American Association of Neurological Surgeons

American Biodefense Action Coalition

American College of Emergency Physicians

American College of Surgeons

American Lung Association

AMMA

Arizona Bioindustry Association, Inc. (AZBio)

ASM

Association of Maternal & Child Health Programs

ATCC

Bavarian Nordic

Big Cities Health Coalition

BioCT

BioNJ

Biotechnology Innovation Organization (BIO)

BioUtah

Blu Zone Bioscience & Supply Chain Solutions

Blueprint Biosecurity

Bugworks

Civitas Networks for Health

Colorado BioScience Association

Congress of Neurological Surgeons

Council of State Bioscience Associations

Dentec Safety Specialists Corp.

eHealth Exchange

Elusys Therapeutics, Inc.

Federation of American Hospitals

FluGen Inc

Genentech, Inc.

Georgetown University

Georgia Life Sciences

GeoVax Labs, Inc.

Global Health Investment Corporation

GSK

Hamilton Grace LLC

Harvard Kennedy School, Belfer Center for Science and International Affairs

Health Industry Distributors Association

Healthcare Distribution Alliance

High Alert Institute

Illinois Biotechnology Innovation Organization, iBIO

Indiana Life Sciences Association

Infectious Diseases Society of America (IDSA)
Institute for Progress
Johns Hopkins Center for Health Security
Life Sciences PA
Maryland Tech Council
Mass General Brigham
Maxter Healthcare Inc
Medical Alley
Medical CBRN Defense Consortium (MCDC)
Michigan Biosciences Industry Association (MichBio)
National Association of County and City Health Officials
Neuroene Therapeutics Inc
New Orleans BioInnovation Center Inc
NewYorkBIO
NMBio
North Carolina Life Sciences Organization
Ohio Life Sciences Association
Premier Inc.
Recce Pharmaceuticals Ltd
Research!America

Roche Diagnostics
SAB Biotherapeutics, Inc
Sanofi
SCbio
Shionogi Inc.
SIGA Technologies
Society for Public Health Education
South Dakota Biotech
Strengthening the Mid-Atlantic Region for Tomorrow (SMART)
Texas Healthcare & Bioscience Institute
The Medical Countermeasures Coalition
Tonix Pharma
Trinity Health
TrippBio, Inc.
True North BioPharm, LLC
Trust for America's Health
United Safety Technology Inc.
University of Nebraska System
Vaccinate Your Family
Valneva USA